Pediatric Blood and Marrow Transplant Consortium

Gamis, Alan S.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Heart, Lung, and Blood Institute (NHLBI)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 1U01HL069254-01
• Application #: 6439084
• Study Section: Special Emphasis Panel (ZHL1-CSR-F (S1))
• Program Officer: Peterson, Charles M
• Project Start: 2001-09-30
• Project End: 2006-08-31
• Budget Start: 2001-09-30
• Budget End: 2002-08-31
• Support Year: 1
• Fiscal Year: 2001
• Total Cost: $400,212

Institution

• Name: Children's Mercy Hosp (Kansas City, MO)
• City: Kansas City
• State: MO
• Country: United States
• Zip Code: 64108

Publications

Shenoy, Shalini; Walters, Mark C; Ngwube, Alex et al. (2018) Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. Biol Blood Marrow Transplant 24:1216-1222

Miggelbrink, Alexandra M; Logan, Brent R; Buckley, Rebecca H et al. (2018) B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood 131:2967-2977

Dietz, Andrew C; Savage, Sharon A; Vlachos, Adrianna et al. (2017) Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Ped Biol Blood Marrow Transplant 23:1422-1428

Dietz, Andrew C; Mehta, Parinda A; Vlachos, Adrianna et al. (2017) Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International C Biol Blood Marrow Transplant 23:726-735

Dietz, Andrew C; Duncan, Christine N; Alter, Blanche P et al. (2017) The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation f Biol Blood Marrow Transplant 23:24-29

Dietz, Andrew C; Lucchini, Giovanna; Samarasinghe, Sujith et al. (2016) Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia. Curr Opin Pediatr 28:3-11

Yanik, Gregory A; Grupp, Stephan A; Pulsipher, Michael A et al. (2015) TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant 21:67-73

Lankester, Arjan C; Locatelli, Franco; Bader, Peter et al. (2015) Will post-transplantation cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant 21:402-11

Pulsipher, M A; Langholz, B; Wall, D A et al. (2015) Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplant 50:1173-9

Pulsipher, Michael A; Carlson, Chris; Langholz, Bryan et al. (2015) IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood 125:3501-8